Future of Aduhelm was in doubt after Medicare restricted coverage to clinical trials
EMA vote deals a setback to controversial $56,000-a-year treatment
Pharma group resurrects pipeline therapy it abandoned as ineffective earlier this year
Bristol-Myers Squibb’s acquisition of Celgene goes ahead after Amgen pays €13.4bn for drug
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices